Featured Research

from universities, journals, and other organizations

Speed Of PSA Rise Helps Predict Survival For Prostate Cancer Patients

Date:
October 1, 2005
Source:
American Society for Therapeutic Radiology and Oncology
Summary:
The clinical outcome for prostate cancer patients who have been treated with hormone therapy and radiation therapy can usually be determined by how rapidly their prostate specific antigen level rises following treatment, according to a report published in the October 1, 2005 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

The clinical outcome for prostate cancer patients who have been treated with hormone therapy and radiation therapy can usually be determined by how rapidly their prostate specific antigen level rises following treatment, according to a report published in the October 1, 2005 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

Doctors at M.D. Anderson Cancer Center in Houston studied 621 men with prostate cancer treated with hormone and radiation therapy between 1989 and 2003 to determine whether clinical failure after their treatment correlated with the speed at which their post treatment PSA level rose. Clinical failure was defined as cancer recurring in the prostate or spreading to other parts of the body.

Researchers found that measuring how quickly the PSA level doubled was a good indicator of subsequent poor clinical outcomes, including cancer developing in other parts of the body or death related to prostate cancer.

Patients whose PSA level doubled within eight months after treatment failure were more likely to have the cancer return or spread to other parts of the body than patients whose PSA did not double in eight months or less. The estimated five-year rate of clinical failure for patients with a PSA doubling time of more than eight months was only 9.4 percent while 60.4 percent of patients whose PSA doubling time was less than or equal to eight months could expect some type of clinical failure.

"The PSA doubling time is an important indicator of how well a patient will recover from prostate cancer," said Andrew K. Lee, M.D., lead author of the study and a radiation oncologist at M.D. Anderson Cancer Center in Houston. "Although clinical outcomes may be positively affected if the patient receives hormone therapy with radiation therapy, a quickly rising PSA level unfortunately still portends poor results for these patients."

###

For more information on radiation therapy for prostate cancer, please visit http://www.rtanswers.org.

ASTRO is the largest radiation oncology society in the world, with more than 8,000 members who specialize in treating patients with radiation therapies. As a leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.


Story Source:

The above story is based on materials provided by American Society for Therapeutic Radiology and Oncology. Note: Materials may be edited for content and length.


Cite This Page:

American Society for Therapeutic Radiology and Oncology. "Speed Of PSA Rise Helps Predict Survival For Prostate Cancer Patients." ScienceDaily. ScienceDaily, 1 October 2005. <www.sciencedaily.com/releases/2005/10/051001101436.htm>.
American Society for Therapeutic Radiology and Oncology. (2005, October 1). Speed Of PSA Rise Helps Predict Survival For Prostate Cancer Patients. ScienceDaily. Retrieved April 17, 2014 from www.sciencedaily.com/releases/2005/10/051001101436.htm
American Society for Therapeutic Radiology and Oncology. "Speed Of PSA Rise Helps Predict Survival For Prostate Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2005/10/051001101436.htm (accessed April 17, 2014).

Share This



More Health & Medicine News

Thursday, April 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com
Is Apathy A Sign Of A Shrinking Brain?

Is Apathy A Sign Of A Shrinking Brain?

Newsy (Apr. 17, 2014) A recent study links apathetic feelings to a smaller brain. Researchers say the results indicate a need for apathy screening for at-risk seniors. Video provided by Newsy
Powered by NewsLook.com
Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Thousands Of Vials Of SARS Virus Go Missing

Thousands Of Vials Of SARS Virus Go Missing

Newsy (Apr. 16, 2014) A research institute in Paris somehow misplaced more than 2,000 vials of the deadly SARS virus. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins